Yazar "Boruban, Melih Cem" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience
    (HUMANA PRESS INC, 2009) Eren, Orhan Onder; Artac, Mehmet; Boruban, Melih Cem; Yavas, Ozlem; Arslan, Ugur; Basaranoglu, Metin
    Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.
  • Küçük Resim
    Öğe
    Correlation of Serum Leptin Level and Waist-to-hip Ratio (WHR) With Overall Survival of Patients With Metastatic Breast Cancer (MBC) Treated With Aromatase Inhibitors (AIs).
    (Amer Soc Clinical Oncology, 2013) Artac, Mehmet; Bozcuk, Hakan; Kıyıcı, Aysel; Eren, Orhan Önder; Boruban, Melih Cem; Özdoğan, Mustafa
    Introduction Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Methods Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Results Median age was 51 years (range 28–75). Median leptin level was 19400 pg/ml (1970–91900) and estradiol level 29.6 pg/ml (4.0–181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was C19400 pg/ml (HR = 0.38; 95% CI: 0.16–0.91). Conclusions This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.
  • Küçük Resim Yok
    Öğe
    Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients?
    (AMER SOC CLINICAL ONCOLOGY, 2012) Artac, Mehmet; Askin, Dudu; Kiyici, Aysel; Eren, Onder Orhan; Oncel, Mufide; Boruban, Melih Cem; Bozcuk, Hakan Sat
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
    (SPRINGER JAPAN KK, 2013) Artac, Mehmet; Bozcuk, Hakan; Kiyici, Aysel; Eren, Orhan Onder; Boruban, Melih Cem; Ozdogan, Mustafa
    Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Median age was 51 years (range 28-75). Median leptin level was 19400 pg/ml (1970-91900) and estradiol level 29.6 pg/ml (4.0-181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was a parts per thousand yen19400 pg/ml (HR = 0.38; 95% CI: 0.16-0.91). This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.